These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 29128052)

  • 1. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.
    Puri P; Sanyal AJ
    Clin Liver Dis; 2018 Feb; 22(1):121-132. PubMed ID: 29128052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.
    Qamar AA
    J Clin Gastroenterol; 2015; 49 Suppl 1():S28-32. PubMed ID: 26447961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gut microbiota and nonalcoholic steatohepatitis].
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A
    Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?
    Betrapally NS; Gillevet PM; Bajaj JS
    Gastroenterology; 2016 Jun; 150(8):1745-1755.e3. PubMed ID: 26948887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
    Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
    Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
    Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.
    van Best N; Jansen PL; Rensen SS
    Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease.
    Akhmedov VA; Gaus OV
    Ter Arkh; 2019 Mar; 91(2):143-148. PubMed ID: 31094185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.
    Aqel B; DiBaise JK
    Nutr Clin Pract; 2015 Dec; 30(6):780-6. PubMed ID: 26449892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.
    Cui Y; Wang Q; Chang R; Zhou X; Xu C
    J Agric Food Chem; 2019 Mar; 67(10):2754-2762. PubMed ID: 30798598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome.
    Quigley EM; Abu-Shanab A; Murphy EF; Stanton C; Monsour HP
    Semin Liver Dis; 2016 Sep; 36(4):312-316. PubMed ID: 27997970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
    Utzeri E; Usai P
    World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial proteins: intestinal guards to protect against liver disease.
    Hendrikx T; Schnabl B
    J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.